

BF₃·Et₂O promoted one-pot expeditious and convenient synthesis of 2-substituted benzimidazoles and 3,1,5-benzoxadiazepines

Vishnu K. Tandon* and Manoj Kumar

Department of Chemistry, University of Lucknow, Lucknow 226007, India

Received 17 November 2003; revised 12 March 2004; accepted 19 March 2004


Abstract—2-Substituted benzimidazoles and 3,1,5-benzoxadiazepines have been synthesized in excellent yields in a single pot by cyclodehydration of *N*-acyl-1,2-phenylenediamines and *N,N'*-diacyl-1,2-phenylenediamines prepared in situ from the corresponding 1,2-phenylenediamines and an acid chloride, respectively.

© 2004 Elsevier Ltd. All rights reserved.

The benzimidazole ring is a crucial pharmacophore in drug discovery. Benzimidazole derivatives are an unique and broad-spectrum class of antirhino/enteroviral agents.¹ Benzimidazoles exhibit significant activity against several viruses including HIV,² herpes (HSV-1),³ RNA,⁴ influenza⁵ and human cytomegalovirus (HCMV).^{2a} In recent years benzimidazoles have been reported to act as topoisomerase I inhibitors,⁶ selective neuropeptide Y Y1 receptor antagonists,⁷ angiotensin II (AII) inhibitors,⁸ inhibitors of HCMV replication,^{2a} 5-HT₃ antagonists in isolated guinea pig ileum,⁹ potential antitumour agents,¹⁰ antimicrobial agents,¹¹ smooth muscle cell proliferation inhibitors,¹² a treatment for interstitial cystitis,¹³ as factor Xa inhibitors¹⁴ and in diverse areas of chemistry.¹⁵

Benzoxadiazepines have been found to possess marked biological effects as CNS stimulants,¹⁶ muscle relaxants,¹⁷ tranquilizers, anticonvulsants,¹⁸ antibacterial and antiinflammatory agents¹⁹ and pesticides and insecticides.¹⁸


A number of synthetic methods have been developed in recent years to uncover a variety of new reagents for the synthesis of 2-substituted benzimidazoles.^{20–26} However, the yields reported in the above methods are moderate or poor. Moreover more than one step is involved in the synthesis of these compounds. Few methods are available in the literature for the synthesis of benzoxadiazepines.^{27–30}



Scheme 1.

During the course of our studies towards the development of new routes to the synthesis of heterocycles, we employed BF₃·Et₂O as a selective reagent for cyclodehydration of *N*-acyl-1,2-phenylenediamines and *N,N'*-diacyl-1,2-phenylenediamines, resulting in the formation of 2-substituted benzimidazoles and 2,4-disubstituted benzoxadiazepines (Scheme 1).

We envisaged that cyclodehydration of *N*-acyl and *N,N'*-diacyl derivatives **4** and **5** with BF₃·Et₂O would lead to the formation of 2-substituted benzimidazoles **2** and 2,4-disubstituted 3,1,5-benzoxadiazepines **3**.



A typical reaction procedure involves the addition of 1,2-phenylenediamines **1** to the acid chloride (1 equiv) at

* Corresponding author. Tel.: +91-522-2322283; fax: +91-522-23266-65; e-mail: vishnutandon@yahoo.co.in

Table 1. Isolated 2-substituted benzimidazoles **2** and 3,1,5-benzoxadiazepines **3** from 1,2-phenylenediamines **1**. All the reactions were complete in 1–2.5 h

Entry	R	R ¹	R ²	Product yield (%)	
				2	3
1	CH ₃	H	H	95	82
2	C ₆ H ₅	H	H	97	88
3	4-Cl-C ₆ H ₄	H	H	98	91
4	4-MeO-C ₆ H ₄	H	H	97	93
5	4-O ₂ N-C ₆ H ₄	H	H	98	90
6	2-C ₅ H ₄ N	H	H	94	92
7	4-C ₅ H ₄ N	H	H	93	90
8	CH ₃ -CH ₂ -CH ₂	H	H	92	83
9	2-Furyl	H	H	94	86
10	CH ₃	Cl	H	92	85
11	CH ₃	H	Cl	93	87
12	C ₆ H ₅	Cl	H	94	92
13	CH ₃	NO ₂	H	93	88
14	C ₆ H ₅	NO ₂	H	95	92

0 °C in dry dioxane and stirring for 30 min at rt to furnish the corresponding *N*-acyl-1,2-phenylenediamine **4**. BF₃·Et₂O in dry dioxane was added to crude **4** and the reaction mixture refluxed for 1–2.5 h at 130 °C. The yields of the 2-substituted benzimidazoles³¹ were excellent (92–98%) and independent of the various substituents present in the precursor (Table 1).

Employing the same procedure reported above but using 2 equiv of acid chloride, 2,4-substituted-3,1,5-benzoxadiazepines **3** were synthesized.³² The yields of **3** were 82–93% and independent of various substituents present in the precursor (Table 1).

Our method for the synthesis of 2-substituted benzimidazoles and 2,4-disubstituted-3,1,5-benzoxadiazepines³³ has the following advantages over previous known methods of synthesis: (i) the precursors *N*-acyl and *N,N'*-diacyl-1,2-phenylenediamines need not be isolated before cyclodehydration; (ii) the cyclodehydration and deacylation can be accomplished in situ in one pot; (iii) BF₃·Et₂O is efficient and tolerant towards a number of substituted aromatics, unsubstituted aliphatics and heterocycles.

In summary, the present communication describes a simple, efficient and convenient synthesis of 2-substituted benzimidazoles and 2,4-disubstituted 3,1,5-benzoxadiazepines in excellent yields using BF₃·Et₂O as the cyclodehydrating and deacylating agent.

References and notes

- Tebbe, M. J.; Spitzer, W. A.; Victor, F.; Miller, S. C.; Lee, C. C.; Sattelberg, T. R., Sr.; McKinney, E.; Tang, C. J. *J. Med. Chem.* **1997**, *40*, 3937–3946.
- (a) Porcari, A. R.; Devivar, R. V.; Kucera, L. S.; Drach, J. C.; Townsend, L. B. *J. Med. Chem.* **1998**, *41*, 1252–1262; (b) Roth, M.; Morningstar, M. L.; Boyer, P. L.; Hughes, S. H.; Buckheit, R. W., Jr.; Michejda, C. J. *J. Med. Chem.* **1997**, *40*, 4199–4207.
- Migawa, M. T.; Girardet, J.-L.; Walker, J. A., II; Koszalka, G. W.; Chamberlain, S. D.; Drach, J. C.; Townsend, L. B. *J. Med. Chem.* **1998**, *41*, 1242–1251.
- Tamm, I.; Sehgal, P. B. *Adv. Virus Res.* **1978**, *22*, 187–258.
- Tamm, I. *Science* **1957**, *126*, 1235–1236.
- (a) Wu, Z.; Jin, S.; Yang, J. M.; Xiav, H.; Sim, S. P.; Liu, A.; Liu, L. F.; LaVoie, E. *Abstracts of The American Chemical Society, Division of Medicinal Chemistry*, 222nd ACS National Meeting, Chicago, IL Aug 26–29, 2001; American Chemical Society: Washington, DC, 2001; 62 (b) Kim, J. S.; Gatto, B.; Yu, C.; Liu, A.; Liu, L. F.; LaVoie, E. *J. Med. Chem.* **1996**, *39*, 992–995.
- (a) Zarrinmayeh, H.; Zimmerman, D. M.; Cantrell, B. E.; Schober, D. A.; Bruns, R. F. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 647–652; (b) Zarrinmayeh, H.; Nunes, A.; Ornstein, P.; Zimmerman, D.; Arnold, B.; Schober, D.; Gackenheimer, S.; Bruns, R.; Hipskind, P.; Britton, T.; Cantrell, B.; Gehlert, D. *J. Med. Chem.* **1998**, *41*, 2709–2719.
- Kohara, Y.; Kubo, K.; Imamiya, E.; Wada, T.; Inada, Y.; Naka, T. *J. Med. Chem.* **1996**, *39*, 5228–5235.
- Lopez, M. L. R.; Benham, B.; Morcillio, M. J.; Tejada, I. D.; Orensanz, L.; Alfaro, M. J.; Martin, M. I. *J. Med. Chem.* **1999**, *42*, 5020–5028.
- Denny, W. A.; Rewcastle, G. W.; Baguley, B. C. *J. Med. Chem.* **1990**, *33*, 814–819.
- (a) Fonseca, T.; Gigante, B.; Gilchrist, T. L. *Tetrahedron* **2001**, *57*, 1793–1799; (b) Parikh, A. R.; Khunt, M. D. *Abstracts of The American Chemical Society, Division of Medicinal Chemistry*, 222nd ACS National Meeting, Chicago, IL Aug 26–29, 2001; American Chemical Society: Washington, DC, 2001; 73.
- Elokda, H. M.; Chai, S. Y.; Sulkowski, T. S. U.S. Patent 5,763,473, June 9, 1998; *Chem. Abstr.* **1998**, *129*, 58784g.
- Iyenger, S.; Nuhlhauser, M. A.; Thor, K. B. U.S. Patent 13,129, 1996; International PCT Patent 33,873, September 18, 1997; *Chem. Abstr.* **1997**, *127*, 293221P.
- Zhao, J.; Arnaiz, D.; Griedel, B.; Sakata, B.; Dallas, J.; Whitlow, M.; Trinh, L.; Post, J.; Liang, A.; Morrissey, M.; Shaw, K. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 963–966.
- Stevenson, C.; Davies, R.; Jeremy, H. *Chem. Res. Toxicol.* **1999**, *12*, 38–45.
- (a) Petigara, R. B.; Yale, H. L. U.S. Patent 4,134,975, 1979; (b) Bristol, J. A.; Yale, H. L. U.S. Patent 4,062,852, 1977.
- Petigara, R. B.; Yale, H. L. U.S. Patent 3,856,801, 1974; *Chem. Abstr.* **1975**, *82*, 31362s.
- Singh, G.; Singh, C.; Kaur, H. *Asian J. Chem.* **1995**, *7*, 735–741. *Chem. Abstr.* **1996**, *124*, 86970e.
- Reddy, P. S. N.; Reddy, P. P.; Padmaja, K.; Shailja, G.; Reddy, D. S. *Indian J. Chem.* **1996**, *35B*, 1110–1112.
- Tempest, P.; Ma, V.; Thomas, S.; Hua, Z.; Kelly, M. G.; Hulme, C. *Tetrahedron Lett.* **2001**, *42*, 4959–4962.
- Deluca, M. R.; Kerwin, S. M. *Tetrahedron* **1997**, *53*, 457–464.
- Ramsden, C. A.; Rose, H. L. *J. Chem. Soc., Perkin Trans. I* **1997**, *16*, 2319–2327.
- Lee, H. I.; Jeoung, E. H.; Lee, C. K. *J. Heterocycl. Chem.* **1996**, *33*, 1711–1716.
- Boido, C.; Boido, V.; Novelli, F.; Paratore, S. *J. Heterocycl. Chem.* **1998**, *35*, 853–858.
- Frachey, G.; Crestini, C.; Bernini, R.; Saladino, R.; Mincione, E. *Heterocycles* **1994**, *38*, 2621–2630.
- Zhen, S.; Huan, G. *Huaxue Tongbao* **1997**, *10*, 55–58.
- Mazurkiewicz, R. *Monatsh. Chem.* **1988**, *119*, 1279–1287.
- Boehringer, C. *Ger.* 955,861, Jan 10, 1957; *Chem. Abstr.* **1957**, *53*, 4317.
- Weidenhagen, R. *Ber.* **1936**, *69(B)*, 2263–2272.

30. Kim, H.-O.; Huber, E. W.; Friedrich, D.; Peet, N. P. *Synthesis* **1994**, 1406–1408.
31. Substituted benzimidazoles **2** reported in Table 1 are known compounds to which the spectroscopic data was compared. Data for entry 8: 2-*n*-propylbenzimidazole: mp 160–162 °C (lit.²⁹ 157–159 °C); ν_{\max} (KBr/cm): 1604 (C=N), 3110 (NH); $^1\text{H NMR}$ (CDCl_3 , 200 MHz, δ ppm): 0.80 (3H, t, $J = 6.5$ Hz, CH_3), 1.93 (2H, m, CH_2), 2.14 (2H, t, $J = 6.5$ Hz, CH_2), 6.80–7.42 (5H, m, Ph and NH); m/z M^+ , 161 ($M+1$), 160.
32. Some of the 3,1,5-benzoxadiazepines reported in Table 1 are known compounds for which satisfactory spectroscopic data were obtained. Data for 2,3-bis(4-methoxyphenyl)-3,1,5-benzoxadiazepine (entry 4): pale yellow powder, mp 124 °C; ν_{\max} (KBr/cm): 1680 (C=N), 1026 (C–O–C); $^1\text{H NMR}$ (CDCl_3 , 200 MHz, δ ppm): 3.85 (6H, s, OCH_3), 6.95 (8H, m, Ph), 7.87 (4H, m, Ph); m/z M^+ , 359 ($M+1$), 105, 77; ^{13}C : 56.0, 114.2, 123.5, 128.3, 130.0, 146.7, 164.0, 164.3; Analysis: calcd for $\text{C}_{22}\text{H}_{18}\text{N}_2\text{O}_3$; C, 73.74; H, 5.02; N, 7.82; found: C, 73.92; H, 5.08; N, 7.94.
33. The detailed spectral data of other benzimidazoles and benzoxadiazepines will be reported in a full paper.